Quince Therapeutics President Charles Ryan to Depart September 8
QNCX has more than doubled off its 52-week low of $15.1.
Summary
Quince Therapeutics announced President Charles Ryan will leave the company on September 8, 2026, adding to a wave of executive departures amid the company's going-concern crisis.
Key Events · Executive and Board Changes · QNCX
-
President Charles Ryan to Depart
President Charles Ryan's last day of employment will be September 8, 2026, as determined on August 23, 2026.
-
Severance Benefits Triggered
Ryan will be eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.
-
Executive Team Turnover
Ryan's departure follows the previously announced conditional resignations of the CEO and COO, leaving the company with a nearly depleted executive leadership team.
-
Going Concern Crisis
The departure comes two weeks after Quince reported a $75.5M Q2 loss and disclosed substantial doubt about its ability to continue as a going concern.
Analysis · QNCX · Life Sciences
President Charles Ryan's departure comes amid a period of severe financial distress for Quince Therapeutics. The company reported a $75.5M Q2 loss and disclosed substantial doubt about its ability to continue as a going concern just two weeks ago. Ryan's exit follows the previously announced conditional resignations of the CEO and COO, signaling a near-complete turnover of the executive team. The departure of the President, a key operational leader, removes another layer of stability at a critical juncture when the company faces an October 6 vote on converting Series C Preferred Stock into 10.99M common shares.
How filings like this one have moved
In the 30 days to Sep 7, 2026, 30% of the 1942 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $32.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.1M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.